433 related articles for article (PubMed ID: 24934993)
1. Coumarin hybrids as novel therapeutic agents.
Sandhu S; Bansal Y; Silakari O; Bansal G
Bioorg Med Chem; 2014 Aug; 22(15):3806-14. PubMed ID: 24934993
[TBL] [Abstract][Full Text] [Related]
2. Coumarin-benzimidazole hybrids: A review of developments in medicinal chemistry.
G AC; Gondru R; Li Y; Banothu J
Eur J Med Chem; 2022 Jan; 227():113921. PubMed ID: 34715585
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
Patil PO; Bari SB; Firke SD; Deshmukh PK; Donda ST; Patil DA
Bioorg Med Chem; 2013 May; 21(9):2434-50. PubMed ID: 23517722
[TBL] [Abstract][Full Text] [Related]
4. A Review on Pharmacological Properties of Coumarins.
Srikrishna D; Godugu C; Dubey PK
Mini Rev Med Chem; 2018; 18(2):113-141. PubMed ID: 27488585
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase (MAO) inhibitory activity: 3-phenylcoumarins versus 4-hydroxy-3-phenylcoumarins.
Delogu GL; Serra S; Quezada E; Uriarte E; Vilar S; Tatonetti NP; Viña D
ChemMedChem; 2014 Aug; 9(8):1672-6. PubMed ID: 24782464
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Huang M; Xie SS; Jiang N; Lan JS; Kong LY; Wang XB
Bioorg Med Chem Lett; 2015 Feb; 25(3):508-13. PubMed ID: 25542589
[TBL] [Abstract][Full Text] [Related]
7. Chemical library design, QSAR modeling and molecular dynamics simulations of naturally occurring coumarins as dual inhibitors of MAO-B and AChE.
Boulaamane Y; Kandpal P; Chandra A; Britel MR; Maurady A
J Biomol Struct Dyn; 2024; 42(4):1629-1646. PubMed ID: 37199265
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.
Pisani L; Muncipinto G; Miscioscia TF; Nicolotti O; Leonetti F; Catto M; Caccia C; Salvati P; Soto-Otero R; Mendez-Alvarez E; Passeleu C; Carotti A
J Med Chem; 2009 Nov; 52(21):6685-706. PubMed ID: 19810674
[TBL] [Abstract][Full Text] [Related]
9. Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Jiang X; Guo J; Lv Y; Yao C; Zhang C; Mi Z; Shi Y; Gu J; Zhou T; Bai R; Xie Y
Bioorg Med Chem; 2020 Jun; 28(12):115550. PubMed ID: 32503694
[TBL] [Abstract][Full Text] [Related]
10. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
Matos MJ; Viña D; Quezada E; Picciau C; Delogu G; Orallo F; Santana L; Uriarte E
Bioorg Med Chem Lett; 2009 Jun; 19(12):3268-70. PubMed ID: 19423346
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Yang HL; Cai P; Liu QH; Yang XL; Li F; Wang J; Wu JJ; Wang XB; Kong LY
Eur J Med Chem; 2017 Sep; 138():715-728. PubMed ID: 28728104
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
Zhang C; Yang K; Yu S; Su J; Yuan S; Han J; Chen Y; Gu J; Zhou T; Bai R; Xie Y
Eur J Med Chem; 2019 Oct; 180():367-382. PubMed ID: 31325784
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
Farina R; Pisani L; Catto M; Nicolotti O; Gadaleta D; Denora N; Soto-Otero R; Mendez-Alvarez E; Passos CS; Muncipinto G; Altomare CD; Nurisso A; Carrupt PA; Carotti A
J Med Chem; 2015 Jul; 58(14):5561-78. PubMed ID: 26107513
[TBL] [Abstract][Full Text] [Related]
14. Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents.
Matos MJ; Herrera Ibatá DM; Uriarte E; Viña D
ChemMedChem; 2020 Mar; 15(6):532-538. PubMed ID: 32037726
[TBL] [Abstract][Full Text] [Related]
15. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Xie SS; Wang X; Jiang N; Yu W; Wang KD; Lan JS; Li ZR; Kong LY
Eur J Med Chem; 2015 May; 95():153-65. PubMed ID: 25812965
[TBL] [Abstract][Full Text] [Related]
16. Coumarin Compounds in Medicinal Chemistry: Some Important Examples from the Last Years.
Pereira TM; Franco DP; Vitorio F; Kummerle AE
Curr Top Med Chem; 2018; 18(2):124-148. PubMed ID: 29595110
[TBL] [Abstract][Full Text] [Related]
17. A review: Biologically active 3,4-heterocycle-fused coumarins.
Salehian F; Nadri H; Jalili-Baleh L; Youseftabar-Miri L; Abbas Bukhari SN; Foroumadi A; Tüylü Küçükkilinç T; Sharifzadeh M; Khoobi M
Eur J Med Chem; 2021 Feb; 212():113034. PubMed ID: 33276991
[TBL] [Abstract][Full Text] [Related]
18. MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
Matos MJ; Vazquez-Rodriguez S; Uriarte E; Santana L; Viña D
Bioorg Med Chem Lett; 2011 Jul; 21(14):4224-7. PubMed ID: 21684743
[TBL] [Abstract][Full Text] [Related]
19. Recent Literature Review on Coumarin Hybrids as Potential Anticancer Agents.
Shaik BB; Katari NK; Seboletswe P; Gundla R; Kushwaha ND; Kumar V; Singh P; Karpoormath R; Bala MD
Anticancer Agents Med Chem; 2023; 23(2):142-163. PubMed ID: 35440315
[TBL] [Abstract][Full Text] [Related]
20. Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins.
Carotti A; Altomare C; Catto M; Gnerre C; Summo L; De Marco A; Rose S; Jenner P; Testa B
Chem Biodivers; 2006 Feb; 3(2):134-49. PubMed ID: 17193252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
